LMAO
Recent VYGR News
- Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/26/2024 08:01:00 PM
- Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results • GlobeNewswire Inc. • 02/28/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:00:24 PM
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:36:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:30:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 08:16:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 08:13:39 PM
- Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:11:54 PM
- Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research • GlobeNewswire Inc. • 02/20/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:06:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:03:00 PM
- Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:34:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:32:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 01/17/2024 09:20:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/17/2024 08:33:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/17/2024 08:21:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:49:46 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/08/2024 09:04:59 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM